Novartis Posts Mixed Third-Quarter Results for Key Drugs
Novartis revenue was roughly in line with consensus, while some key drugs beat expectations and others fell short, Bernstein analysts said. A one-off reimbursement benefit helped Cosentyx beat forecasts; the body is truncated after mentioning gene therapy Z…
Novartis's third-quarter revenue was roughly in line with consensus estimates, with some key drugs beating expectations and others falling short, Bernstein analysts say in a research note. A one-off reimbursement benefit helped immunology drug Cosentyx beat consensus forecasts, while gene therapy Z…